White label ELPA - ClinicalTrials.eu

Study on the Effects of 30% vs. 60% Oxygen Levels at Birth for Improving Development in Premature Infants

Recruiting

3 1 1 1
Investigated diseases:
- Premature baby
Investigated drugs:
- Oxygen Ph.eur.
Study of Capivasertib and Fulvestrant for Patients with High-Risk Lobular Breast Cancer

Recruiting

2 1 1 1
Investigated drugs:
- Capivasertib
- Fulvestrant
Study on the Safety and Effects of Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Recruiting

3 1 1 1
Investigated diseases:
- Congenital cystic kidney disease
Investigated drugs:
- Tolvaptan
Study on HUVR-CARTemis-1 Therapy for Patients with Relapsed Multiple Myeloma After Allogeneic Transplant Using a Drug Combination

Recruiting

2 1 1 1
Investigated diseases:
- Plasma cell myeloma
Investigated drugs:
Study on the Effectiveness of Infliximab, Ustekinumab, and Vedolizumab for Patients with Resistant Crohn’s Disease

Recruiting

2 1 1 1
Investigated diseases:
- Crohn’s disease
Investigated drugs:
Study of Patritumab Deruxtecan for Patients with Advanced or Metastatic Solid Tumors

Recruiting

2 1 1
Investigated diseases:
- Neoplasm
Investigated drugs:
- Patritumab Deruxtecan
+2
Study Comparing Vedolizumab and Infliximab for Children Aged 6-17 with Ulcerative Colitis

Recruiting

2 1 1 1
Investigated diseases:
- Colitis ulcerative
Investigated drugs:
- Infliximab
- Vedolizumab
Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Recruiting

3 1 1
Investigated diseases:
Investigated drugs:
+17
Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Recruiting

3 1 1 1
Investigated diseases:
- Plasma cell myeloma refractory
Investigated drugs:
+10
Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Recruiting

3 1 1
Investigated diseases:
- Systemic lupus erythematosus
Investigated drugs:
+5

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies